Nine different antibody–drug conjugates (ADCs) are currently approved as cancer
treatments, with dozens more in preclinical and clinical development. The primary goal of …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

The cGAS-STING pathway is essential for immune defense against microbial pathogens and
malignant cells; as such, STING is an attractive target for cancer immunotherapy. However …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody–drug conjugates (ADCs) are a family of targeted therapeutic agents for the
treatment of cancer. ADC development is a rapidly expanding field of research, with over 80 …

The primary purpose of ADCs is to increase the efficacy of anticancer medications by
minimizing systemic drug distribution and targeting specific cells. Antibody conjugates …

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody
conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a …

Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …

Cyclobutanes are increasingly used in medicinal chemistry in the search for relevant
biological properties. Important characteristics of the cyclobutane ring include its unique …